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Abstract
Background: Policymakers and stakeholders need immediate access to many types of research evidence to make
informed decisions about the full range of questions that may arise regarding health systems.
Methods: We examined all types of research evidence about governance, financial and delivery arrangements, and
implementation strategies within health systems contained in Health Systems Evidence (HSE) (www.healthsystemsevidence.
org). The research evidence types include evidence briefs for policy, overviews of systematic reviews, systematic reviews of
effects, systematic reviews addressing other questions, systematic reviews in progress, systematic reviews being planned,
economic evaluations, and health reform and health system descriptions. Specifically, we describe their distribution across
health system topics and domains, trends in their production over time, availability of supplemental content in various
languages, and the extent to which they focus on low- and middle-income countries (LMICs), as well as (for systematic
reviews) their methodological quality and the availability of user-friendly summaries.
Results: As of July 2013, HSE contained 2,629 systematic reviews of effects (of which 501 are Cochrane reviews), 614
systematic reviews addressing other questions, 283 systematic reviews in progress, 186 systematic reviews being planned,
140 review-derived products (evidence briefs and overviews of systematic reviews), 1,669 economic evaluations, 1,092
health reform descriptions, and 209 health system descriptions. Most systematic reviews address topics related to delivery
arrangements (n = 2,663) or implementation strategies (n = 1,653) with far fewer addressing financial (n = 241) or
governance arrangements (n = 231). In addition, 2,928 systematic reviews have been quality appraised with moderate
AMSTAR ratings found for reviews addressing governance (5.6/11), financial (5.9/11), and delivery (6.3/11) arrangements and
implementation strategies (6.5/11); 1,075 systematic reviews have no independently produced user-friendly summary and
only 737 systematic reviews have an LMIC focus. Literature searches for half of the systematic reviews (n = 1,584, 49%) were
conducted within the last five years.
Conclusions: Greater effort needs to focus on assessing whether the current distribution of systematic reviews corresponds
to policymakers’ and stakeholders’ priorities, updating systematic reviews, increasing the quality of systematic reviews, and
focusing on LMICs.
“Congress has provided vital funding for research
that compares the effectiveness of different
treatments, and this should help reduce uncertainty
about which treatments are best. But we also need to
fund research that compares the effectiveness of
different systems of care – to reduce our uncertainty
about which systems work best for communities.
These are empirical, not ideological questions”.
Atul Gawande, The New Yorker, 1 June 2009, p. 44
Background
Policymakers and stakeholders need immediate access to
many types of research evidence to make informed deci-
sions about the full range of questions they may have re-
garding health system arrangements and implementation
strategies (with the latter including those aimed at
supporting the use of research evidence at the level of citi-
zens, providers, organizations, and policymakers). While
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decision about health systems (e.g., institutional con-
straints, interests of stakeholders affected by decisions,
and the values and preferences of the public), research evi-
dence can also help support and inform their efforts to
strengthen or reform health systems or get cost-effective
programs, services, and drugs to those who need them.
Atul Gawande got it mostly right: “these are empirical,
not just ideological questions”.
The timeliness of research evidence was one of two
factors that emerged with some consistency in a system-
atic review of the factors that increased the prospects for
research use in policymaking [1]. When the research lit-
erature has already been identified, selected, appraised
and synthesized in a systematic and transparent way,
health system policymakers can move directly to assessing
how much confidence they can place in the review (i.e., its
quality), the local applicability of the review’s findings, and
what the findings mean for their setting [2]. Stakeholders,
such as professional associations and citizen groups, also
need timely access to many types of research evidence to
inform their advocacy efforts focused on health systems.
Researchers and research funding agencies need system-
atic reviews to identify gaps in knowledge about health
systems (both primary studies and systematic reviews) and
domains that could benefit from overviews of systematic
reviews, as well as to put the findings of any new health
systems research in the context of existing research [1].
Questions about the comparative effectiveness of one
health system arrangement over another (such as using
nurses rather than doctors to deliver certain forms of
care) are one of the types of questions for which
policymakers and stakeholders may turn to systematic
reviews [3]. The likelihood of them being misled by re-
search evidence about comparative effectiveness is lower
and confidence in what effects they can expect from a
health system arrangement is higher with a systematic
review than with an individual study [4]. However, what
the quotation from Atul Gawande fails to point out is
that policymakers and stakeholders can also turn to sys-
tematic reviews to address questions best answered
using qualitative and mixed-methods studies, such as
questions regarding patients’ views about and experi-
ences with problems encountered in health systems and
with options for addressing these problems [5]. Further-
more, given often constrained resources, policymakers
also need to consider value for money in any decision they
make, which requires access to locally applicable eco-
nomic evaluations about the various policy levers at their
disposal. To further support their decisions, policymakers
m a ya l s ow i s ht ot u r nt od e s c r i p t i o n so fh e a l t hr e f o r m s
undertaken in other jurisdictions to better understand
what was done, how, and why, as well as to descriptions
of other health systems to help determine the local
applicability of research evidence generated in these sys-
tems to their own.
Policymakers and stakeholders are relatively well served
by existing databases such as Medline (particularly when
validated search strategies are employed) [6,7] and the
Cochrane Library (which contains both the Cochrane
Database of Systematic Reviews and the Database of
Reviews of Effects) if their questions about compara-
tive effectiveness pertain to clinical programs and ser-
vices or to drugs [3]. They are also well served by
Health Evidence™ (www.healthevidence.org) if their
questions about comparative effectiveness pertain to
public health programs and services [8]. More recently,
if their questions pertain to the governance, financial
and delivery arrangements within which programs, ser-
vices and drugs are provided, and to implementation
strategies for these programs, services and drugs, they
are well served by Health Systems Evidence (HSE)
(www.healthsystemsevidence.org). HSE provides a com-
prehensive inventory of nine types of research evidence,
namely evidence briefs for policy (i.e., a document that
summarizes how the findings from a number of system-
atic reviews pertain to a pressing problem, select options
for addressing the problem, and key implementation con-
siderations), overviews of systematic reviews, systematic
reviews of effects, systematic reviews addressing other
types of questions, systematic reviews in progress, system-
atic reviews being planned, economic evaluations, health
reform descriptions, and health system descriptions [9,10].
All of these existing databases are further strengthened
by significant efforts from a large and growing number
of groups to package, quality appraise, and facilitate as-
sessments of local applicability of systematic reviews [5].
In addition, recent efforts have drawn on HSE to document
the types of study designs included in reviews addressing
health-system interventions [11]. To our knowledge, there
have been no efforts to develop a comprehensive profile of
the available research evidence addressing topics related to
governance, financial and delivery arrangements within
health systems, and implementation strategies that can sup-
port change in health systems, and the products derived
from them.
Methods
We drew on the global stock of the nine types of re-
search evidence related to health systems contained in
HSE as of July 2013. HSE draws its content from all of
the major sources of each of the nine types of research
evidence (e.g., Cochrane Library for systematic reviews
of effects and protocols for such reviews, Economic
Evaluation Database for economic evaluations, and
Health Policy Monitor for health reform descriptions)
[12,Unpublished data]. Each record contained in HSE is
categorized according to a taxonomy of health system
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primary care), coded according to key features (e.g., sys-
tematic reviews are coded according to their metho-
dological quality and the countries in which included
studies were conducted) [13], and made available in se-
ven languages. All of the eligibility assessments and
coding are done by two independent raters. The me-
thods underpinning the development and continuous
updating of HSE are described in a separate manuscript
[Unpublished data].
The data related to, and coding categories associated
with, each of the records contained in HSE were used to
calculate descriptive statistics that profile: 1) the distribu-
tion of research evidence, particularly systematic reviews,
across health system topics and domains; 2) trends over
time in how recently the literature was searched for sys-
tematic reviews and in the volume of publication for all
types of research evidence; 3) the distribution of system-
atic reviews according to their methodological quality
(assessed using AMSTAR (A MeaSurement Tool to As-
sess the quality of systematic Reviews) [13], as well as
trends over time in the distribution of average quality
scores; 4) the availability of user-friendly summaries (for
systematic reviews) and links to additional content (for all
types of research evidence) by source, type of system-
atic review, and language; and 5) the distribution of re-
search evidence according to the type of low- and
middle-income country (LMIC) focus. When summar-
izing our findings we often focus on systematic re-
views, either because the data only apply to this type of
research evidence (e.g., AMSTAR ratings) or because
this type of research evidence is likely to be of greatest
immediate relevance to health system policymakers
and stakeholders.
Results and Discussion
HSE contains (as of July 2013) 6,613 documents ad-
dressing topics related to health systems, which include:
 140 review-derived products (94 evidence briefs and
46 overviews of systematic reviews);
 2629 systematic reviews of effects
∘ 501 Cochrane reviews of which one in five have
been produced by the Effective Practice and
Organization of Care (EPOC) review group
(111/501, 22%);
 614 systematic reviews addressing other types of
questions (e.g., reviews of observational studies that
often assess the scale of problems or associations
between variables and reviews of qualitative studies
that often assess the nature of problems and/or how
and why interventions work);
 283 systematic reviews in-progress (i.e., systematic
review protocols);
 186 systematic reviews being planned (i.e., systematic
review titles that have been registered and for which a
protocol is being prepared);
 1669 economic evaluations;
 1092 health reform descriptions; and
 209 descriptions of health systems.
Topics and domains addressed
Most systematic reviews address topics related to de-
livery arrangements (n = 2,663) or implementation
strategies (n = 1,653) in whole or in part, whereas
much smaller numbers of systematic reviews address
financial arrangements (n = 241) or governance arrange-
ments (n = 231) (Table 1). Within the delivery arrange-
ments category, ‘by whom care is provided’ (i.e., human
resources) represents the largest sub-category (n = 1,426,
of which 342 addressed multi-disciplinary teams). This is
followed by “how care is designed to meet consumers’
needs” (n = 972, of which 562 addressed packages of care/
care pathways/disease management) and “where care is
provided” (n = 720, of which 427 addressed the site of ser-
vice delivery). Within the implementation strategies cat-
egory, consumer-targeted strategies represent the largest
sub-category (n = 1,208), followed by provider-targeted
strategies (n = 622) and organization-targeted strat-
egies (n = 65). Within the governance arrangements
category, organizational authority (i.e., what decisions
can organizations like hospitals make and how) represents
the largest sub-category (n = 89) and “consumer and
stakeholder involvement” the second largest (n = 71).
Within the financial arrangements category, remunerating
providers (i.e., how providers are paid) represents the lar-
gest sub-category (n = 106), followed by “incentivizing
consumers” (n = 85) and “financing systems” (i.e., how
revenue is raised for health systems and services) (n = 56).
Many systematic reviews address particular diseases (n =
1,819), sectors (n = 1,634), providers (n = 1,582), and tech-
nologies (n = 667) (Table 2). Within the groupings of dis-
eases indexed by HSE, the top five categories of diseases
addressed by reviews are mental health and addictions (n =
962), cardiovascular disease (n = 343), diabetes (n = 276),
maternal and child health (n = 284), and cancer (n = 222).
While we found that approximately half (n = 1,582, 49%) of
the systematic reviews in HSE address topics related to one
or more types of providers, most within this grouping are
focused on physicians (n = 945) and nurses (n = 692) and,
to a lesser extent, allied health professionals (n = 391) as
compared to pharmacists (n = 154) and lay/community
health workers (n = 137). For the grouping of health system
sectors, a relatively large number of reviews address primary
care (n = 569), hospital care (n = 555), home care (n = 626),
public health (n = 393), and rehabilitation (n = 195), but few
address long-term care (n = 64). The majority of reviews ad-
dressing health system arrangements and implementation
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Health system topics All documents
(n = 6,613)
Evidence
briefs for
policy
(n = 94)
Overviews of
systematic
reviews
(n = 46)
Systematic
reviews of
effects**
(n = 2,629)
Systematic reviews
addressing other
types of questions
(n = 614)
Systematic
reviews in
progress
(n = 283)
Systematic reviews
being planned
(n = 186)
Economic
evaluations
(n = 1,669)
Health reform
descriptions
(n = 1,092)
Governance arrangement 1360 21% 46 49% 10 22% 117 4% 114 19% 15 5% 12 6% 80 5% 966 88%
￿ Policy authority 890 13% 24 26% 5 11% 26 1% 31 5% 8 3% 5 3% 23 1% 768 70%
￿ Organizational authority 648 10% 20 21% 4 9% 37 1% 52 8% 2 1% 3 2% 28 2% 502 46%
￿ Commercial authority 280 4% 8 9% 3 7% 17 1% 17 3% 1 0% 1 1% 9 1% 224 21%
￿ Professional authority 441 7% 16 17% 3 7% 33 1% 34 6% 2 1% 1 1% 25 1% 327 30%
￿ Consumer & stakeholder
involvement
335 5% 21 22% 4 9% 35 1% 36 6% 4 1% 2 1% 6 0% 227 21%
Financial arrangement 1240 19% 47 50% 14 30% 171 7% 70 11% 23 8% 17 9% 153 9% 745 68%
￿ Financing systems 604 9% 22 23% 6 13% 32 1% 24 4% 6 2% 2 1% 23 1% 489 45%
￿ Funding organizations 230 3% 8 9% 4 9% 22 1% 9 1% 4 1% 0 0% 5 0% 178 16%
￿ Remunerating providers 400 6% 23 24% 11 24% 73 3% 33 5% 7 2% 1 1% 22 1% 230 21%
￿ Purchasing products &
services
454 7% 9 10% 3 7% 20 1% 11 2% 3 1% 2 1% 91 5% 315 29%
￿ Incentivizing consumers 487 7% 16 17% 7 15% 72 3% 13 2% 10 4% 12 6% 46 3% 311 28%
Delivery arrangement 5590 85% 71 76% 40 87% 2145 82% 518 84% 225 80% 128 69% 1581 95% 882 81%
￿ How care is designed to
meet consumers’ needs
2849 43% 32 34% 16 35% 808 31% 164 27% 84 30% 45 24% 1078 65% 622 57%
￿ By whom care is provided 2767 42% 58 62% 23 50% 1097 42% 329 54% 107 38% 59 32% 586 35% 508 47%
￿ Where care is provided 1677 25% 31 33% 13 28% 579 22% 141 23% 61 22% 33 18% 417 25% 402 37%
￿ With what supports is care
provided
1792 27% 27 29% 23 50% 756 29% 152 25% 69 24% 25 13% 339 20% 401 37%
Implementation strategy 3031 46% 50 53% 25 54% 1425 54% 228 37% 145 51% 64 34% 633 38% 461 42%
￿ Consumer-targeted strategy 2297 35% 35 37% 16 35% 1078 41% 130 21% 114 40% 52 28% 489 29% 383 35%
￿ Provider-targeted strategy 1103 17% 38 40% 18 39% 502 19% 120 20% 34 12% 15 8% 203 12% 173 16%
￿ Organization-targeted
strategy
104 2% 2 2% 5 11% 37 1% 28 5% 12 4% 2 1% 18 1% 0 0%
*This table does not provide data related to health system descriptions as they are not categorized in Health Systems Evidence according to health system topics. As a result, the total number of documents listed
here is 6,613 but the total including the 209 health system descriptions indexed in Health Systems Evidence is 6,822.
**Systematic reviews of effects include 501 Cochrane reviews of which 111 (22%) have been produced by the Effective Practice and Organization of Care (EPOC) review group.
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2Table 2 Number (and %) of documents addressing particular domains, by type of document*
Domains All documents
(n = 6,613)
Evidence
briefs for
policy
(n = 94)
Overviews of
systematic
reviews
(n = 46)
Systematic
reviews of
effects**
(n = 2,629)
Systematic reviews
addressing other
types of questions
(n = 614)
Systematic reviews
in progress (n = 283)
Systematic reviews
being planned
(n = 186)
Economic
evaluations
(n = 1,669)
Health reform
descriptions
(n = 1,092)
Diseases 3833 58% 49 52% 21 46% 1590 60% 229 37% 172 61% 83 45% 1279 77% 410 38%
Infectious diseases 808 12% 18 19% 4 9% 217 8% 35 6% 23 8% 22 12% 423 25% 66 6%
￿ HIV 295 4% 5 5% 2 4% 123 5% 19 3% 13 5% 16 9% 100 6% 17 2%
￿ Tuberculosis 99 1% 4 4% 2 4% 31 1% 9 1% 2 1% 2 1% 42 3% 7 1%
￿ Malaria 60 1% 8 9% 0 0% 11 0% 7 1% 7 2% 1 1% 26 2% 0 0%
￿ Diarrhoeal disease 52 1% 1 1% 0 0% 14 1% 0 0% 2 1% 1 1% 33 2% 1 0%
￿ Lower respiratory infections 71 1% 0 0% 0 0% 25 1% 2 0% 1 0% 2 1% 39 2% 2 0%
Non-communicable diseases 1884 28% 6 6% 9 20% 742 28% 111 18% 78 28% 30 16% 658 39% 250 23%
￿ Cancer 584 9% 3 3% 3 7% 183 7% 39 6% 18 6% 3 2% 209 13% 126 12%
￿ Cardiovascular
disease
661 10% 2 2% 2 4% 306 12% 37 6% 26 9% 11 6% 204 12% 73 7%
￿ Diabetes 493 7% 2 2% 4 9% 234 9% 42 7% 14 5% 8 4% 119 7% 70 6%
￿ Alzheimer and other dementias 97 1% 1 1% 0 0% 46 2% 8 1% 7 2% 3 2% 12 1% 20 2%
￿ Chronic obstructive pulmonary
disease
91 1% 1 1% 1 2% 40 2% 6 1% 7 2% 5 3% 24 1% 7 1%
Other 1833 28% 31 33% 13 28% 898 34% 129 21% 84 30% 37 20% 413 25% 228 21%
￿ Maternal and child health 678 10% 17 18% 5 11% 242 9% 42 7% 35 12% 12 6% 207 12% 118 11%
￿ Accidents 190 3% 1 1% 0 0% 84 3% 10 2% 8 3% 9 5% 52 3% 26 2%
￿ Mental health and addictions 1089 16% 15 16% 10 22% 637 24% 83 14% 42 15% 16 9% 155 9% 131 12%
Technologies 1805 27% 25 27% 9 20% 562 21% 105 17% 39 14% 15 8% 634 38% 416 38%
￿ Drugs 1047 16% 19 20% 9 20% 345 13% 59 10% 16 6% 11 6% 323 19% 265 24%
￿ Devices 174 3% 1 1% 0 0% 59 2% 6 1% 4 1% 1 1% 54 3% 49 4%
￿ Diagnostics 464 7% 2 2% 1 2% 76 3% 14 2% 9 3% 1 1% 200 12% 161 15%
￿ Surgery 379 6% 4 4% 0 0% 119 5% 32 5% 11 4% 3 2% 110 7% 100 9%
Sectors 3689 56% 44 47% 20 43% 1368 52% 266 43% 138 49% 51 27% 1025 61% 777 71%
￿ Primary care 1138 17% 23 24% 13 28% 460 17% 109 18% 38 13% 9 5% 206 12% 280 26%
￿ Home care 604 9% 6 6% 3 7% 287 11% 39 6% 26 9% 4 2% 134 8% 105 10%
￿ Hospital care 1537 23% 5 5% 3 7% 445 17% 110 18% 49 17% 24 13% 375 22% 526 48%
￿ Rehabilitation 345 5% 3 3% 0 0% 180 7% 15 2% 11 4% 3 2% 56 3% 77 7%
￿ Long-term care 252 4% 3 3% 3 7% 53 2% 11 2% 11 4% 3 2% 22 1% 146 13%
￿ Public health 1085 16% 20 21% 9 20% 349 13% 44 7% 47 17% 12 6% 395 24% 209 19%
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2Table 2 Number (and %) of documents addressing particular domains, by type of document* (Continued)
Providers 3098 47% 33 35% 22 48% 1264 48% 318 52% 88 31% 41 22% 645 39% 687 63%
￿ Physician 1951 30% 14 15% 13 28% 767 29% 178 29% 50 18% 21 11% 345 21% 563 52%
￿ Nurse 1259 19% 17 18% 8 17% 526 20% 166 27% 40 14% 15 8% 284 17% 203 19%
￿ Pharmacist 338 5% 5 5% 4 9% 133 5% 21 3% 13 5% 7 4% 93 6% 62 6%
￿ Allied health professional 828 13% 9 10% 9 20% 334 13% 57 9% 27 10% 10 5% 170 10% 212 19%
￿ Lay/community health worker 322 5% 10 11% 3 7% 114 4% 23 4% 23 8% 8 4% 77 5% 64 6%
*This table does not provide data related to health system descriptions as they are not categorized in Health Systems Evidence according to topic domains. As a result, the total number of documents listed here is
6,613 but the total including the 209 health system descriptions indexed in Health Systems Evidence is 6,822.
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2strategies related to the technologies category address drugs
(n = 404) and surgery (n = 151) with far fewer addressing
diagnostics (n = 90) and devices (n = 65).
Trends in production over time
We found that 2,893 of the 3,243 systematic reviews
(89%) reported the last year the literature was searched
and, based on the available data, 1,584 (49%) were
conducted within the last five years (i.e., since 2008)
(Figure 1). Of the 350 reviews for which we do not have
the last year the literature was searched, 199 (57%) were
published within the last five years. Our sub-analysis of
Cochrane reviews revealed that most of the 501 reviews
(n = 493, 98%) reported the last year the literature was
searched and 332 (66%) of these were conducted within
the last five years, while only 153 (30%) were up to date
within the last two years, which is the Cochrane Collab-
oration’s recommended timeframe for updating reviews
[14]. For overviews of systematic reviews, 37 of 46 (80%)
reported the last year the literature was searched, and 26
of these (56%) were conducted within the last five years
(Figure 1).
Regarding the year of publication, we found that 90 of
the 94 (96%) evidence briefs for policy, 273 of the 283
(96%) systematic reviews in progress (i.e., protocols that
had not yet been turned into a full review), all of the 186
systematic reviews being planned, 1,275 of the 1,669 (76%)
economic evaluations (note that only those conducted in
the last 10 years are indexed in HSE), 423 of the 1,092
(39%) descriptions of health reforms, and 101 of the 209
(48%) descriptions of health systems were published
within the last five years (Figure 2).
Methodological quality of systematic reviews
Most systematic reviews (n = 2,928, 90%) indexed in
HSE have been quality appraised using AMSTAR and
their methodological quality is (on average) moderate
(i.e., between 4 and 7 out of 11), which has remained
relatively consistent over time (Table 3 and Figure 3).
The average methodological quality of reviews addressing
delivery arrangements (6.3/11) and implementation strat-
egies (6.3/11) was somewhat higher than those addressing
financial (5.9/11) and governance arrangements (5.6/11).
However, methodological quality differs substantially
according to the type of systematic review. Those pro-
duced by the Cochrane Collaboration are of high quality
(i.e., between 9 and 11 out of 11) across all second-level
topic domains (with none falling outside this range). In
contrast, systematic reviews of effects (which include
Cochrane reviews) are of moderate quality (with no
second-level category averages falling outside the range of
4.8–7.4) and quantitative reviews addressing other types
of questions were low to moderate quality (with no aver-
ages falling outside the range of 3.6–5.4).
Availability of user-friendly summaries and links to
additional content
The majority (n = 2,168, 67%) of systematic reviews now
have at least one user-friendly (English-language) sum-
mary available from one of the eight groups in the world
that package, quality appraise and/or facilitate assess-
ments of the local applicability of systematic reviews
(Table 4). The largest producers of these structured
decision-relevant summaries for reviews about health
system arrangements are the DARE (n = 1,962, 90% of
those with at least one summary) and the Cochrane Li-
brary through its plain language summaries of reviews
(n = 505, 23%). However, these review summaries are
not targeted specifically at health system policymakers
and stakeholders. The three groups representing the
next largest shares of summaries of reviews about health
system arrangements – Rx for Change (n = 211, 10%),
Figure 1 Last year literature was searched for systematic reviews and overviews of systematic reviews.
Wilson et al. Health Research Policy and Systems 2013, 11:32 Page 7 of 13
http://www.health-policy-systems.com/content/11/1/32Health Evidence™ (n = 231, 11%), and Australasian
Cochrane Centre (n = 85, 4%) – are more targeted at
these groups. A number of reviews also have one or
more summaries available in Spanish (n = 474) and
French (n = 391), but fewer summaries are available in
the four remaining languages (14 for each of Arabic and
Russian, 36 for Chinese and 1 for Portuguese).
Across all documents contained in HSE (n = 6,613),
more than half (n = 3,893, 59%) have no links to one or
more independently produced structured decision-
relevant summaries (Table 5). Most documents have
links to a scientific abstract from PubMed (n = 4,549),
the Cochrane Library (n = 1,994, of which 299 have been
translated into Spanish and 28 have been translated into
French) or from another publisher (n = 4,281, of which
55 have been translated into French). Two thirds of the
documents have a link to a full-text report that can be
accessed without a subscription (n = 4,638, 70%); how-
ever, countries that have a national license to the
Cochrane Library can access full Cochrane reviews (n =
501) and protocols of Cochrane reviews (n = 283) for
free as well.
Low- and middle-income country (LMIC) focus
We found 1,228 (19%) documents in HSE that have an
LMIC focus (Table 6), half of which are systematic re-
views of effects (n = 614, 50%) and a lower percentage of
which are economic evaluations (n = 280, 23%), system-
atic reviews addressing other types of questions (n =
123, 10%), and health system descriptions (n = 92, 7%).
The 737 systematic reviews with an LMIC focus (which
are the subset of documents described in Table 6 that
we focus on here) were most often the result of in-
cluding at least one study conducted in an LMIC set-
ting (n = 712, 97%) with far fewer identified as having
an LMIC setting as the target of the document (n =
1 9 3 ,2 6 % )o rh a v i n ga tl e a s to n ea u t h o rf r o ma nL M I C
(n = 118, 16%).
Similar to the full set of reviews contained in HSE, the
systematic reviews with an LMIC focus most often
addressed topics related to delivery arrangements (n =
590) and implementation strategies (n = 394) in whole
or in part, with far fewer addressing financial (n = 74)
and governance arrangements (n = 55). The most com-
mon sub-categories under delivery arrangements con-
taining systematic reviews with an LMIC focus were “by
whom is care provided” (n = 319), “how care is designed
to meet consumers’ needs” (n = 236), “where care is
provided” (n = 171), and “with what supports is care
provided” (n = 161). The majority of systematic reviews
within the implementation strategies category address
consumer-targeted strategies (n = 310), while fewer ad-
dressing provider-targeted strategies (n = 132). Within
the governance arrangements category, policy authority
(n = 20) represents the largest sub-category and within
the financial arrangements category, “incentivizing con-
sumers” (n = 29), “remunerating providers” (n = 27) and
“financing systems” (n = 26) represent the largest sub-
categories.
The systematic reviews identified as having an LMIC
focus also have a similar profile to the global stock of re-
views in terms of how recently they were conducted and
their quality. As outlined in Figure 4, slightly more than
half of the reviews (n = 403, 54%) were conducted within
the last five years (since 2008) and of the 12 overviews
of systematic reviews with an LMIC focus 6 (50%) were
conducted within the last five years. In addition, we
found that all of the systematic reviews in progress (n =
25), systematic reviews being planned (n = 17), and
health reform descriptions (n = 3), as well as 237 of 280
Figure 2 Publication dates for documents.
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http://www.health-policy-systems.com/content/11/1/32(85%) economic evaluations, 58 of 60 (97%) evidence
briefs for policy and 42 of 92 (46%) health system de-
scriptions, with an LMIC focus, were published within
the last five years. In terms of quality, almost all of the
reviews with an LMIC focus (n = 696, 94%) have been
appraised for methodological quality using AMSTAR
and (on average) have a moderate quality score (range =
4.2–7.7 out of a possible score of 11) across topic do-
mains (Table 3).
Conclusions
We have provided a detailed examination of the global
stock of research evidence relevant to health systems
policymaking. Systematic reviews of effects are the most
common of the nine types of research evidence in HSE
(n = 2,629, 40%). Most systematic reviews address topics
related to delivery arrangements (n = 2,663) or imple-
mentation strategies (n = 1,653) in whole or in part,
which may reflect a tendency among more clinically
Table 3 Mean quality rating* of systematic reviews addressing particular health system topics, by focus and type of
systematic review
Domains** All reviews
(n = 2,928)†
All LMIC-focused
reviews (n = 696)†
All types of systematic reviews†
Cochrane systematic
reviews of effects
(n = 484)†
Systematic
reviews
of effects
(n = 2408)†
(Quantitative) Systematic
reviews addressing other
types of questions***
(n = 520)†
Governance arrangement (n = 197) 5.6 5.4 10.3 6.6 4.5
￿ Policy authority (n = 46) 5.1 5.4 9.9 5.7 4.5
￿ Organizational authority (n = 69) 5.5 7.0 10.3 6.6 4.7
￿ Commercial authority (n = 33) 4.6 4.1 10.5 5.4 3.6
￿ Professional authority (n = 50) 5.4 4.8 10.3 6.4 4.3
￿ Consumer & stakeholder involvement
(n = 60)
5.7 5.3 10.3 6.5 4.7
Financial arrangement (n = 219) 5.9 6.6 9.9 6.4 4.4
￿ Financing systems (n = 50) 5.1 5.7 10.5 6.1 3.7
￿ Funding organizations (n = 25) 4.7 5.5 9.3 5.0 3.5
￿ Remunerating providers (n = 97) 5.5 5.8 9.4 5.6 5.4
￿ Purchasing products & services
(n = 27)
4.4 4.2 10.0 4.8 3.9
￿ Incentivizing consumers (n = 83) 7.0 7.7 10.0 7.4 4.5
Delivery arrangement (n = 2,395) 6.3 6.8 9.9 6.7 4.5
￿ How care is designed to meet
consumers' needs (n = 883)
6.5 6.7 10.0 6.7 5.0
￿ By whom care is provided
(n = 1,276)
6.2 6.6 9.9 6.6 4.5
￿ Where care is provided (n = 642) 6.6 7.3 9.9 7.0 4.9
￿ With what supports is care provided
(n = 807)
6.1 6.8 10.0 6.4 4.5
Implementation strategy
(n = 1,519)
6.3 6.8 9.8 6.5 4.9
￿ Consumer-targeted strategy
(n = 1,118)
6.5 6.9 10.0 6.7 4.9
￿ Provider-targeted strategy
(n = 562)
6.0 6.5 9.5 6.2 5.0
￿ Organization-targeted strategy
(n = 53)
5.9 6.4 9.7 6.2 5.4
†The numbers refer to the number of reviews in each category with a completed quality appraisal. The total numbers for each column are as follows: All reviews
= 3,243; All LMIC-focused reviews = 737; Cochrane systematic reviews of effects = 501; Systematic reviews of effects = 2,629; Systematic reviews addressing other
types of questions = 614.
*Due to the fact that the denominators for quality appraisal scores can vary using the AMSTAR tool when a question is deemed to be 'Not applicable', we
standardized the mean quality score by: 1) converting each score into a percentage, 2) calculating the average of the percentage scores for each cell of the table,
and 3) using the average percentage score to calculate the mean score out of 11.
**The numbers beside each category refer to the number of quality appraisals available.
***This excludes systematic reviews of qualitative evidence that require a different approach to quality appraisal.
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intervention and then (faced with feasibility and other
concerns raised by policymakers and stakeholders) to
examine the effects of alternative ways of delivering the
intervention or implementing it on a large scale. Half
(49%) of the systematic reviews presented findings based
on searches conducted within the last five years (since
2008), quality ratings ranged from 5.6 (for governance
arrangements) to 6.3 (for delivery arrangements and im-
plementation strategies) out of a possible 11, nearly one in
four reviews (n = 737, 23%) contain at least one study
from a LMIC, and 1,075 reviews have no independently
produced structured decision-relevant summary.
This study has one key strength and one potential limi-
tation. Our analysis represents the first effort (at least to
our knowledge) to systematically assess the global stock of
nine types of research evidence relevant to health systems
policymaking. Moreover, we have developed an approach
to real-time reporting for all of the tables and figures in-
cluded in our analysis, which will allow us to update the
tables and figures at any time and identify changes over
time. The potential limitation of our study is that, by rely-
ing on one data source for our analysis, we have missed
including relevant systematic reviews. However, we believe
this possibility to be remote given that HSE systematically
culls relevant documents from a number of databases
(Medline, Cochrane Database of Systematic Reviews, three
databases – DARE, PROSPERO, Economic Evaluations
Database – from the Centre for Reviews and Disse-
mination, Rx for Change, and the Cochrane Qualitative
and Implementation Methods Group’s reference database
for qualitative reviews) and many other sources such as
listservs (e.g., EvidenceUpdates and PAHO EQUIDAD)
and websites (e.g., AHRQ, Campbell Collaboration, EPPI-
Centre and several more). As a result, searching other
sources would be unlikely to identify many documents.
For those interested in reviewing the full list of sources
and methods used to build and continuously update HSE
we provide these details in a separate manuscript [Unpub-
lished data].
Based on the profile of research evidence provided
here, particularly the profile of systematic reviews, we
Figure 3 Mean quality (AMSTAR) score.
Table 4 Number (and %) of user-friendly summaries available for systematic reviews, by type of systematic review*
Source of summary All reviews
(n = 3,243)**
Systematic reviews of effects
(n = 2,629)
Systematic reviews addressing other
types of questions (n = 614)
Australasian Cochrane Centre Policy Liaison Initiative 85 3% 85 3% 0 0%
Cochrane Library (plain language summaries) 505 16% 504 19% 1 0%
Database of Review of Effects 1,962 60% 1,821 69% 141 23%
Effective Health Care Research Programme Consortium 14 0% 14 1% 0 0%
Health Evidence™ 231 7% 228 9% 3 0%
Reproductive Health Library 21 1% 21 1% 0 0%
Rx for Change 211 7% 201 8% 10 2%
SUPPORT 34 1% 34 1% 0 0%
*This table only provides counts of links available in English.
**1,075 systematic reviews have no independently produced user-friendly summary.
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http://www.health-policy-systems.com/content/11/1/32Table 5 Number of links available for all types of document, by language*
Links Language
English Arabic Chinese French Portuguese Russian Spanish
No. of user-friendly summaries
￿ 0 3,893 7,855 7,835 7,479 7,868 7,855 7,411
￿ 1 3,260 14 32 375 1 14 438
￿ 2 507 0 2 15 0 0 19
￿ 3 141 0 0 0 0 0 1
￿ 44 4 0 0 0 0 0 0
￿ 5+ 24 0 0 0 0 0 0
Abstracts
￿ PubMed 4,549 0 0 0 0 0 0
￿ Cochrane Library 1,994 0 0 28 0 0 299
￿ Publisher 4,281 0 0 55 0 0 0
Full-text 4,638 63 63 731 2 62 152
*Includes IberoAmerican (for Spanish) and BVS Salud (for Portuguese).
Table 6 Number (and %) of documents addressing health system topics, by type of low- and middle-income country
(LMIC) focus
Health system topics Type of LMIC focus
Any category*
(n = 1,228)
Target of
document (n = 648)
At least one LMIC
author (n = 392)
At least one
LMIC study
included (n = 781)
Governance arrangement 117 10% 77 12% 46 12% 84 11%
￿ Policy authority 57 5% 46 7% 25 6% 40 5%
￿ Organizational authority 36 3% 25 4% 14 4% 29 4%
￿ Commercial authority 18 1% 16 2% 7 2% 14 2%
￿ Professional authority 26 2% 13 2% 6 2% 22 3%
￿ Consumer & stakeholder involvement 25 2% 15 2% 12 3% 19 2%
Financial arrangement 166 14% 120 19% 82 21% 108 14%
￿ Financing systems 62 5% 51 8% 25 6% 46 6%
￿ Funding organizations 18 1% 12 2% 5 1% 14 2%
￿ Remunerating providers 51 4% 33 5% 22 6% 42 5%
￿ Purchasing products & services 42 3% 33 5% 27 7% 14 2%
￿ Incentivizing consumers 59 5% 44 7% 27 7% 41 5%
Delivery arrangement 944 77% 472 73% 341 87% 618 79%
￿ How care is designed to meet
consumers' needs
485 39% 318 49% 220 56% 248 32%
￿ By whom care is provided 445 36% 180 28% 141 36% 340 44%
￿ Where care is provided 287 23% 165 25% 120 31% 193 25%
￿ With what supports is care provided 202 16% 52 8% 40 10% 168 22%
Implementation strategy 516 42% 207 32% 154 39% 407 52%
￿ Consumer-targeted strategy 390 32% 151 23% 112 29% 318 41%
￿ Provider-targeted strategy 195 16% 85 13% 63 16% 147 19%
￿ Organization-targeted strategy 17 1% 7 1% 3 1% 12 2%
*Of these documents, 737 are systematic reviews.
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priorities to enhance the usefulness of research evidence
about health systems and support its use by policymakers
and stakeholders. First, there is a need to support efforts
to regularly update systematic reviews, as doing so will
ensure that policymakers and stakeholders have access
to the most recent synthesized research evidence. As
outlined in our findings, half of the systematic reviews
in HSE were conducted five or more years ago and a
large proportion of those produced by the Cochrane
Collaboration have also not been updated within their
recommended timeline of two years. Such efforts could
be supported (at least partially) by funders of system-
atic reviews providing resources both for new system-
atic reviews and for updatinge x i s t i n gr e v i e w s( e . g . ,b y
identifying reviews that address timely policy questions
but are out of date).
Second, there is a need to increase the average quality
of systematic reviews. This is particularly evident for sys-
tematic reviews addressing questions other than effect-
iveness and/or for those addressing topics related to
governance and financial arrangements (many of which
are reviews addressing other types of questions), which
generally scored lower for quality as compared to re-
views addressing questions of effectiveness. Registering ti-
tles and protocols for systematic reviews and implementing
specific quality standards as part of the registration process
is a promising mechanism that may help increase the over-
all quality of reviews. This requirement from the Cochrane
Collaboration contributes (at least in part) to the average
level of quality for Cochrane reviews being significantly
higher than the rest of the reviews in HSE. In addition,
PROSPERO [15] now offers an international prospective
register of systematic reviews requiring minimum meth-
odological standards based on the PRISMA statement [16].
These efforts could be further supported by journals requir-
ing systematic reviews to be registered in order to be con-
sidered for publication.
It should be noted that the AMSTAR tool was
designed originally for reviews of effects. However, the
fundamental methodological requirements for reviews
that include quantitative evidence remain the same and
where they differ there is an option to mark a question
as “not applicable” to the score. As noted in our results,
we did not conduct quality appraisals of reviews that
draw exclusively on qualitative research evidence given
that there is currently no quality appraisal tool available
(at least to our knowledge) that takes into account the
unique methods and approaches to data analysis used in
these types of reviews (although two of us – MGW and
JNL – are currently finalizing a tool that will be able to
be used for this purpose).
Third, there is a need to use the global stock of sys-
tematic reviews to start developing global guidance to
support evidence-informed policies about health systems
[17-19]. However, the utility of such guidelines is
dependent upon the availability of systematic reviews ad-
dressing the full range topics related to governance, finan-
cial and delivery arrangements within health systems, and
about implementation strategies that can support change
in health systems. This will require diversifying the types
of topics addressed in systematic reviews (particularly for
governance and financial arrangements or for increasingly
important topic-specific domains such as long-term care,
which are relatively underserved in the current global
stock) as well as ensuring relevance to LMICs (for which
there are comparatively few reviews). Addressing this
could also include conducting assessments of whether the
current distribution of systematic reviews corresponds to
policymakers’ and stakeholders’ priorities.
Figure 4 Last year literature was searched for systematic reviews and overviews of systematic reviews with an LMIC focus.
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